Breaks Categories: News

MondayDec 04, 2017 9:04 am

CannabisNewsBreaks – Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) Provides 2018 Strategy Update Regarding Growth Plans

Licensed Canadian cannabis cultivation company Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) this morning provided an update regarding its growth plans for 2018. The company’s incoming president and CEO Nick Dean intends to focus on meeting the expected surge in demand in the recreational cannabis sector through strategic partnerships and by increasing Emblem’s total production capacity. Dean also intends to ramp up patient acquisition in the medical cannabis market utilizing the company’s strengths and quality products. “Ultimately it’s about being relentlessly driven to deliver a strong return on investment and a solid balance sheet. We will also be mindful of strategic…

Continue Reading

FridayDec 01, 2017 11:41 am

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Posts Q3 Results, Operational Update

Abcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) recently released financial results for the three and nine months ended September 30, 2017. Among other highlights from the third quarter, the company reported $43.4 million in cash, cash equivalents and marketable securities which provides a strong position for expansion plans for its high-tech Vanluven facility. Abcann also reported revenues of $614,000 for the nine months ended September 30, 2017, a considerable increase compared to $211,00 during the same period in 2016. Additionally, the company provided an update on operations, including the company’s strategy moving forward. “ABcann’s vision is to create a successful…

Continue Reading

FridayDec 01, 2017 10:46 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Announces Stock, Option and Warrant Transactions

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced various stock, option and warrant transactions. The news release states, “Following issuance of these common shares, Lexaria will have 69,674,919 common shares issued and outstanding. No commissions or placement fees have been paid related to the funds received from these warrants exercised. Proceeds will be used for general corporate purposes.” No shares were sold or registered in the United States. In addition, John Docherty, President of Lexaria Bioscience Corp., recently issued a clip discussing the company's technology…

Continue Reading

TuesdayNov 28, 2017 9:33 am

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Research Arm’s Patent Filing for Use of Specific Cannabis Strain Acknowledged by US Patent Office

Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) today announced that its research arm, Cannevert Therapeutics Ltd. (“CTL”), received an acknowledgement letter with the filing number of US 62/558,021 from the US Patent and Trademark Office (“USPTO”) for the filing it made in September for use of a specific cannabis strain to enhance the actions of opioid analgesics.  Veritas CEO, Dr. Lui Franciosi commented, “We are pleased with Cannevert’s latest submission to protect its discovery of a cannabis strain that could potentially reduce the dose and side effects of clinically used opioids while maintaining a good pain relieving effect for…

Continue Reading

MondayNov 27, 2017 9:15 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Set to Present at LD Micro Main Event; Reports Warrant Exercise

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced that it will be presenting at the upcoming 10th annual LD Micro Main Event taking place December 5-7 in Los Angeles, California. Additionally, the company is filing its annual Form 10K which includes financial statements that will be available today at the Securities and Exchange Commission's website (www.sec.gov). Lexaria also said that through the exercise of warrants and a compensation option certificate previously granted, the company has received US $118,913. The compensation option certificate was exercised at…

Continue Reading

WednesdayNov 22, 2017 9:28 am

CannabisNewsBreaks – Veritas Pharma Inc.’s (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) CTL Subsidiary Inks Letter of Intent with FDI of Puerto Rico to Initiate Human Trials of CTL-X

Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) recently announced that its 80% owned subsidiary, Cannevert Therapeutics Ltd. ("CTL"), signed a letter of intent with the Fundación de Investigación (“FDI”) in San Juan, Puerto Rico, to conduct the first human study of CTL-X for the treatment of pain. The study of CTL-X, CTL’s lead cannabis strain for pain, will be conducted in two stages to assess the treatment’s analgesic effects. “We are pleased to see Cannevert’s lead strain for pain is finally heading into human trials. It’s important to us to move quickly into this next phase of providing clinical…

Continue Reading

ThursdayNov 16, 2017 9:13 am

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Presenting at Cannabis-Based Science & Medicine Conference

InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) this morning said that it will be presenting twice at the Biopharma Forum on 'Cannabis-Based Science & Medicine' conference. The company will present on Thursday, November 30 and Friday, December 1 at the conference taking place in Denver, CO. The company’s chief scientific officer, Dr. Sazzad Hossain, will be presenting a lecture titled "Epidermolysis to Glaucoma - Identifying Pathology Candidates for Cannabis-Based Treatments." Among other areas of interest, the lecture will shine a light on InMed’s methods of identifying disease targets for cannabinoid compound treatments. To view the full press release, visit http://cnw.fm/9nvGz About…

Continue Reading

WednesdayNov 15, 2017 9:20 am

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Adds Key Individuals to Board and Executive Team

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) today announced that it has added Mr. Rick Fitzgerald to the Board of Directors and Dr. Michael Bumby to the executive team as Chief Financial Officer. Fitzgerald brings a wealth of strategic marketing and senior leadership experience in the alcoholic beverage and tobacco industries while Bumby adds extensive financial, international and capital markets experience. Paul Lucas, Chair of ABcann’s board of directors, stated, “We are pleased to welcome two outstanding individuals to ABcann and believe their domestic and global business experience will be a significant asset to the Company.” To view the full…

Continue Reading

MondayNov 13, 2017 3:16 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Covered in November ‘Let’s Toke Business’ Report Alongside Canopy Growth (TSX: WEED)

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, has been featured in the November issue of ‘Let’s Toke Business.’ The report draws similarities between Lexaria and Canopy Growth (TSX: WEED), as both companies have had major breakouts on the stock market recently. The ability of Lexaria’s technology to expand into other markets was mentioned in the report, as well the possibility that non-cannabis applications could demonstrate an even greater potential. On November 9, Lexaria announced that it filed a new patent application with the U.S. Patent and Trademark…

Continue Reading

ThursdayNov 09, 2017 10:43 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Announces Filing of New Patent Application with USPTO

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced that it has filed a new patent application with the U.S. Patent and Trademark Office (“USPTO”) covering the use of its DehydraTECH™ technology for the delivery of phosphodiesterase type 5 (PDE5) inhibitors. Existing products occupying this space include Viagra™ (sildenafil) and Cialis™ (tadalafil). Per the update, a common complaint regarding existing PDE5 inhibitors relates to the slow-acting nature of the substances. Lexaria believes that its patented DehydraTECH™ technology, building on existing research with cannabinoid delivery, will…

Continue Reading